Shen Jie, Sun Dong, Yu Shengpeng, Fu Jingshu, Wang Xiaohua, Wang Shulin, Xie Zhao
National & Regional United Engineering Laboratory of Tissue Engineering, Department of Orthopaedics, Southwest Hospital, Army Medical University, Chongqing, China.
Department of Orthopaedics, Dujiangyan Medical Center, Dujiangyan, Sichuan, China.
Bone Joint Res. 2021 Jan;10(1):31-40. doi: 10.1302/2046-3758.101.BJR-2020-0229.R1.
Treatment of chronic osteomyelitis (COM) for young patients remains a challenge. Large bone deficiencies secondary to COM can be treated using induced membrane technique (IMT). However, it is unclear which type of bone graft is optimal. The goal of the study was to determine the clinical effectiveness of bone marrow concentrator modified allograft (BMCA) versus bone marrow aspirate mixed allograft (BMAA) for children with COM of long bones.
Between January 2013 and December 2017, 26 young patients with COM were enrolled. Different bone grafts were applied to repair bone defects secondary to IMT procedure for infection eradication. Group BMCA was administered BMCA while Group BMAA was given BMAA. The results of this case-control study were retrospectively analyzed.
Patient infection in both groups was eradicated after IMT surgery. As for reconstruction surgery, no substantial changes in the operative period (p = 0.852), intraoperative blood loss (p = 0.573), or length of hospital stay (p = 0.362) were found between the two groups. All patients were monitored for 12 to 60 months. The median time to bone healing was 4.0 months (interquartile range (IQR) 3.0 to 5.0; range 3 to 7) and 5.0 months (IQR 4.0 to 7.0; range 3 to 10) in Groups BMCA and BMAA, respectively. The time to heal in Group BMCA versus Group BMAA was substantially lower (p = 0.024).
IMT with BMCA or BMAA may attain healing in large bone defects secondary to COM in children. The bone healing time was significantly shorter for BMCA, indicating that this could be considered as a new strategy for bone defect after COM treatment. Cite this article: 2021;10(1):31-40.
年轻患者慢性骨髓炎(COM)的治疗仍然是一项挑战。COM继发的大骨缺损可采用诱导膜技术(IMT)治疗。然而,尚不清楚哪种类型的骨移植是最佳的。本研究的目的是确定骨髓浓缩器改良同种异体骨(BMCA)与骨髓抽吸物混合同种异体骨(BMAA)治疗儿童长骨COM的临床效果。
2013年1月至2017年12月,纳入26例年轻COM患者。应用不同的骨移植材料修复IMT术后继发的骨缺损以根除感染。BMCA组给予BMCA,BMAA组给予BMAA。对本病例对照研究的结果进行回顾性分析。
两组患者经IMT手术后感染均得以根除。至于重建手术,两组之间在手术时间(p = 0.852)、术中失血量(p = 0.573)或住院时间(p = 0.362)方面均未发现实质性变化。所有患者均接受了12至60个月的监测。BMCA组和BMAA组的骨愈合中位时间分别为4.0个月(四分位间距(IQR)3.0至5.0;范围3至7)和5.0个月(IQR 4.0至7.0;范围3至10)。BMCA组的愈合时间明显短于BMAA组(p = 0.024)。
采用BMCA或BMAA的IMT可能使儿童COM继发的大骨缺损实现愈合。BMCA的骨愈合时间明显更短,表明这可被视为COM治疗后骨缺损的一种新策略。引用本文:2021;10(1):31-40。